rethinkTHC Search
Menu
Study breakdown

Survey of 505 Australian GPs finds growing acceptance of medicinal cannabis but widespread knowledge gaps

Cross SectionalModerate evidence
The takeaway

Most Australian GPs had received patient inquiries about medicinal cannabis, but only half felt comfortable discussing it, and two-thirds felt they lacked adequate knowledge.

Healthcare professionals, medical educators, and readers interested in medicinal cannabis access and prescribing trends.

85% of GPs got patient questions; only 22% had prescribed

What the researchers found

85.3% of GPs received patient inquiries about medicinal cannabis in the prior three months, but only 52.3% felt comfortable discussing it. Just 21.8% had prescribed a cannabis product, and 66.9% felt they had inadequate knowledge.

Why it matters

Six years after medicinal cannabis became available in Australia, GPs remain the primary prescribers but many feel underprepared, highlighting a gap between patient demand and practitioner readiness.

The numbers in context

505 GPs surveyed; 85.3% had patient inquiries; 52.3% comfortable discussing; 21.8% had prescribed; 66.9% felt inadequate knowledge. GPs rated opioids, benzodiazepines, and chemotherapy drugs as more hazardous than cannabis.

How the study worked

Cross-sectional study using a 42-item online questionnaire completed by 505 Australian GPs attending an educational seminar between November 2021 and February 2022. Results were compared to a 2017 survey to track changes over time.

What this study cannot tell us

GPs attending educational seminars may not represent all GPs. Self-selection bias likely. Some GPs incorrectly believed CBD causes addiction and driving impairment, suggesting misinformation. Cross-sectional design.

How to read the evidence

Large survey with comparison to earlier data, though self-selected sample limits generalizability.

When this study was published

Published in 2022 with data from 2021-2022.

The bigger picture

The gap between patient interest and GP confidence in medicinal cannabis is a global pattern seen across multiple countries, suggesting systemic issues with medical education rather than country-specific barriers.

Questions still open

  • What specific educational interventions would most effectively improve GP knowledge? Does GP comfort with cannabis prescribing correlate with patient outcomes?

Common questions

How has GP acceptance of medicinal cannabis changed since 2017?
Support for prescribing cannabis for palliative care, cancer pain, chemotherapy nausea, and epilepsy increased between 2017 and 2022. However, support for prescribing for mental health conditions like depression and anxiety remained lower.
What misconceptions did GPs hold about cannabis?
Some GPs incorrectly believed CBD (cannabidiol) could cause addiction and driving impairment, which does not align with current evidence. This suggests a need for better educational resources.

Read the original research

Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021-2022 survey.

BMC primary care, 23(1), 330

Citation

Bawa, Zeeta; McCartney, Danielle; Manocha, Ramesh; McGregor, Iain S. (2022). Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021-2022 survey.. BMC primary care, 23(1), 330. https://doi.org/10.1186/s12875-022-01946-x

Explore the wider topic